Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Celgene Reports Record Third Quarter 2009 Operating and Financial Results
EntreMed Reports Second Quarter 2009 Financial Results
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
EntreMed Reports First Quarter 2009 Financial Results
EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results
EntreMed Presents Initial Clinical Results for ENMD-2076
EntreMed Focuses on Development of ENMD-2076
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
EntreMed to Present at the New York Society of Security Analysts Industry Conference
EntreMed Reports Clinical Program Progress and Company Update
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
EntreMed to Present at BioPartnering Europe Conference
EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
EntreMed Reports Second Quarter 2008 Financial Results
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
EntreMed to Present at the BIO 2008 Annual International Convention
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
EntreMed's ENMD-2076 Demonstrates Antitumor Activity in Multiple Myeloma Model
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference - Jun 1 2008 9:09PM
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor - Jun 1 2008 9:09PM
EntreMed Reports First Quarter 2008 Financial Results - Jun 1 2008 9:08PM
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
EntreMed Receives Nasdaq Deficiency Notice
EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
